What You Should Know:
Life sciences investment firm OrbiMed announced $3.5 billion in commitments for its latest private investment funds, including $1.5 billion for OrbiMed Private Investments VIII, $800 million for OrbiMed Asia Partners IV, and $1.2 billion for OrbiMed Royalty & Credit Opportunities III.
The three new funds include a broad range of medical institutions, university endowments, foundations, pension funds and sovereign wealth funds.
– OrbiMed Private Investments VIII invests primarily in venture capital stage opportunities in North America and Europe, with a focus on biotechnology, medical device, and diagnostics companies. This fund targets investments from $10 million to $100 million across approximately 40 portfolio companies.
– OrbiMed Asia Partners IV invests primarily in China and India, from venture capital through growth stage across biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. This fund targets investments f